<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Cardiol</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Cardiology</journal-title></journal-title-group><issn pub-type="ppub">2380-6583</issn><issn pub-type="epub">2380-6591</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10034667</article-id><article-id pub-id-type="pmcid-ver">PMC10034667.1</article-id><article-id pub-id-type="pmcaid">10034667</article-id><article-id pub-id-type="pmcaiid">10034667</article-id><article-id pub-id-type="pmid">36947031</article-id><article-id pub-id-type="doi">10.1001/jamacardio.2023.0228</article-id><article-id pub-id-type="publisher-id">hoi230007</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US</article-title><subtitle>National Health and Nutrition Examination Surveys, 2013 to March 2020</subtitle><alt-title alt-title-type="headline">Statin Use for Primary Prevention of ASCVD by Race, Ethnicity, and 10-Year Risk in the US</alt-title><alt-title alt-title-type="running-head">Statin Use for Primary Prevention of ASCVD by Race, Ethnicity, and 10-Year Risk in the US</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jacobs</surname><given-names initials="JA">Joshua A.</given-names></name><degrees>PharmD</degrees><xref rid="hoi230007aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Addo</surname><given-names initials="DK">Daniel K.</given-names></name><degrees>MS</degrees><xref rid="hoi230007aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheutlin</surname><given-names initials="AR">Alexander R.</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="hoi230007aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Derington</surname><given-names initials="CG">Catherine G.</given-names></name><degrees>PharmD</degrees><degrees>MS</degrees><xref rid="hoi230007aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Essien</surname><given-names initials="UR">Utibe R.</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="hoi230007aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="hoi230007aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Navar</surname><given-names initials="AM">Ann Marie</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="hoi230007aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="hoi230007aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hernandez</surname><given-names initials="I">Inmaculada</given-names></name><degrees>PharmD</degrees><degrees>PhD</degrees><xref rid="hoi230007aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lloyd-Jones</surname><given-names initials="DM">Donald M.</given-names></name><degrees>MD</degrees><degrees>ScM</degrees><xref rid="hoi230007aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>King</surname><given-names initials="JB">Jordan B.</given-names></name><degrees>PharmD</degrees><degrees>MS</degrees><xref rid="hoi230007aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hoi230007aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rao</surname><given-names initials="S">Shreya</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="hoi230007aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Herrick</surname><given-names initials="JS">Jennifer S.</given-names></name><degrees>MS</degrees><xref rid="hoi230007aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bress</surname><given-names initials="AP">Adam P.</given-names></name><degrees>PharmD</degrees><degrees>MS</degrees><xref rid="hoi230007aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Pandey</surname><given-names initials="A">Ambarish</given-names></name><degrees>MD</degrees><degrees>MSCS</degrees><xref rid="hoi230007aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="hoi230007aff1"><label>1</label>Intermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City</aff><aff id="hoi230007aff2"><label>2</label>Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City</aff><aff id="hoi230007aff3"><label>3</label>Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at the University of California, Los Angeles</aff><aff id="hoi230007aff4"><label>4</label>Center for the Study of Healthcare Innovation, Implementation &amp; Policy, Greater Los Angeles VA Healthcare System, Los Angeles, California</aff><aff id="hoi230007aff5"><label>5</label>Division of Cardiology, University of Texas Southwestern Medical Center, Dallas</aff><aff id="hoi230007aff6"><label>6</label>Division of Clinical Pharmacy, University of California, San Diego</aff><aff id="hoi230007aff7"><label>7</label>Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois</aff><aff id="hoi230007aff8"><label>8</label>Institute for Health Research, Kaiser Permanente Colorado, Aurora</aff><aff id="hoi230007aff9"><label>9</label>Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City</aff><aff id="hoi230007aff10"><label>10</label>Deputy Editor, Diversity, Equity, and Inclusion, <italic toggle="yes">JAMA Cardiology</italic></aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> January 25, 2023.</p><p content-type="published-online"><bold>Published Online:</bold> March 22, 2023. doi:<uri content-type="doi">10.1001/jamacardio.2023.0228</uri></p><corresp id="hoi230007cor1"><bold>Corresponding Author:</bold> Joshua A. Jacobs, PharmD, Intermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT 84112-5820 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="joshua.jacobs@utah.edu">joshua.jacobs@utah.edu</email>); Ambarish Pandey, MD, MSCS, Division of Cardiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9047 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ambarish.pandey@utsouthwestern.edu">ambarish.pandey@utsouthwestern.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Bress and Pandey had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design</italic>: Jacobs, Zheutlin, Lloyd-Jones, Rao, Bress, Pandey.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data</italic>: Jacobs, Addo, Zheutlin, Derington, Essien, Navar, Hernandez, King, Herrick, Bress, Pandey.</p><p><italic toggle="yes">Drafting of the manuscript</italic>: Jacobs, Essien, Bress, Pandey.</p><p><italic toggle="yes">Critical revision of the manuscript for important intellectual content</italic>: Jacobs, Addo, Zheutlin, Derington, Navar, Hernandez, Lloyd-Jones, King, Rao, Herrick, Bress, Pandey.</p><p><italic toggle="yes">Statistical analysis</italic>: Jacobs, Addo, Zheutlin, Herrick, Bress, Pandey.</p><p><italic toggle="yes">Administrative, technical, or material support</italic>: Jacobs, Zheutlin.</p><p><italic toggle="yes">Supervision</italic>: Bress, Pandey.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Derington reports research funds to her institution from Amarin Pharma. Dr Navar reported grants from Bristol Myers Squibb, Esperion, Amgen, and Janssen and personal fees from AstraZeneca, Boehringer Ingelheim Bayer, Janssen, Eli Lilly, Novo Nordisk, Novartis, New Amsterdam, Cerner, and Pfizer outside the submitted work. Dr Hernandez reported consulting fees from Pfizer and Bristol Myers Squibb and is supported by the National Heart, Lung, and Blood institute. Dr Lloyd-Jones reported serving as an unpaid fiduciary officer of the American Heart Association. Dr King is supported by the National Heart, Lung, and Blood institute. Dr Bress reports research funds to his institution from Amarin Pharma and Amgen and consultant work for Amarin Pharma. Dr Pandey reported research support from the Gilead Sciences Research Scholar Program, the National Institute on Aging GEMSSTAR grant, and the National Institute on Minority Health and Disparities; grant funding outside the submitted work from Applied Therapeutics and Myovista; honoraria outside the submitted work for serving as an advisor/consultant for Tricog Health, Eli Lilly, Cytokinetics, Rivus, Roche Diagnostics, Pieces Technologies, Palomarin, Emmi Solutions, and Axon; and nonfinancial support from Pfizer and Merck. No other disclosures were reported.</p><p><bold>Disclaimer:</bold> Dr Navar is deputy editor of <italic toggle="yes">JAMA Cardiology</italic> but was not involved in any of the decisions regarding review of the manuscript or its acceptance.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-HOI230007-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2023-03-22T10:00"><day>22</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2023</year></pub-date><volume>8</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">431897</issue-id><fpage>443</fpage><lpage>452</lpage><history><date date-type="received"><day>8</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>25</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>22</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-22 00:25:14.460"><day>22</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright 2023 American Medical Association. All Rights Reserved.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamacardiol-e230228.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamacardiol-e230228.pdf">jamacardiol-e230228.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/cardiology/fullarticle/10.1001/jamacardio.2023.0228"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" xlink:title="correction" vol="8" journal-id="JAMA Cardiol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC10209820"><article-title>Error in Figure</article-title><volume>8</volume><issue>7</issue><date><day>24</day><month>5</month><year>2023</year></date><fpage>710</fpage><lpage>710</lpage><source>JAMA Cardiology</source><pub-id pub-id-type="doi">10.1001/jamacardio.2023.1358</pub-id><pub-id pub-id-type="pmcid">PMC10209820</pub-id><pub-id pub-id-type="pmid">37223916</pub-id></related-article><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-hoi230007-1"><title>Question</title><p>What is the prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease (ASCVD) by race and ethnicity according to 10-year risk of ASCVD?</p></sec><sec id="ab-hoi230007-2"><title>Findings</title><p>In this cross-sectional analysis of the National Health and Nutrition Examination Surveys representing 39.4 million US adults, Black and Hispanic participants had significantly lower statin use than White participants. Having health insurance or a routine location for health care were significantly associated with increased statin use across race and ethnicity groups.</p></sec><sec id="ab-hoi230007-3"><title>Meaning</title><p>The findings in this study indicate that racial and ethnic disparities in the use of statins for primary prevention across all strata of ASCVD risk are associated with poor access to care among individuals of self-reported Black and Hispanic race and ethnicity.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This cross-sectional study evaluates statin use for primary prevention of atherosclerotic cardiovascular disease in the US by 10-year risk and by race and ethnicity.</p></abstract><abstract><sec id="ab-hoi230007-4"><title>Importance</title><p>The burden of atherosclerotic cardiovascular disease (ASCVD) in the US is higher among Black and Hispanic vs White adults. Inclusion of race in guidance for statin indication may lead to decreased disparities in statin use.</p></sec><sec id="ab-hoi230007-5"><title>Objective</title><p>To evaluate prevalence of primary prevention statin use by race and ethnicity according to 10-year ASCVD risk.</p></sec><sec id="ab-hoi230007-6"><title>Design, Setting, and Participants</title><p>This serial, cross-sectional analysis performed in May 2022 used data from the National Health and Nutrition Examination Survey, a nationally representative sample of health status in the US, from 2013 to March 2020 (limited cycle due to the COVID-19 pandemic), to evaluate statin use for primary prevention of ASCVD and to estimate 10-year ASCVD risk. Participants aged 40 to 75 years without ASCVD, diabetes, low-density lipoprotein cholesterol levels 190 mg/dL or greater, and with data on medication use were included.</p></sec><sec id="ab-hoi230007-7"><title>Exposures</title><p>Self-identified race and ethnicity (Asian, Black, Hispanic, and White) and 10-year ASCVD risk category (5%-&lt;7.5%, 7.5%-&lt;20%, &#8805;20%).</p></sec><sec id="ab-hoi230007-8"><title>Main Outcomes and Measures</title><p>Prevalence of statin use, defined as identification of statin use on pill bottle review.</p></sec><sec id="ab-hoi230007-9"><title>Results</title><p>A total of 3417 participants representing 39.4 million US adults after applying sampling weights (mean [SD] age, 61.8 [8.0] years; 1289 women [weighted percentage, 37.8%] and 2128 men [weighted percentage, 62.2%]; 329 Asian [weighted percentage, 4.2%], 1032 Black [weighted percentage, 12.7%], 786 Hispanic [weighted percentage, 10.1%], and 1270 White [weighted percentage, 73.0%]) were included. Compared with White participants, statin use was lower in Black and Hispanic participants and comparable among Asian participants in the overall cohort (Asian, 25.5%; Black, 20.0%; Hispanic, 15.4%; White, 27.9%) and within ASCVD risk strata. Within each race and ethnicity group, a graded increase in statin use was observed across increasing ASCVD risk strata. Statin use was low in the highest risk stratum overall with significantly lower rates of use among Black (23.8%; prevalence ratio [PR], 0.90; 95% CI, 0.82-0.98 vs White) and Hispanic participants (23.9%; PR, 0.90; 95% CI, 0.81-0.99 vs White). Among other factors, routine health care access and health insurance were significantly associated with higher statin use in Black, Hispanic, and White adults. Prevalence of statin use did not meaningfully change over time by race and ethnicity or by ASCVD risk stratum.</p></sec><sec id="ab-hoi230007-10"><title>Conclusions and Relevance</title><p>In this study, statin use for primary prevention of ASCVD was low among all race and ethnicity groups regardless of ASCVD risk, with the lowest use occurring among Black and Hispanic adults. Improvements in access to care may promote equitable use of primary prevention statins in Black and Hispanic adults.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>